Two studies published within days of each other asked different questions about the same drugs and the same disease. Put together they say something useful about when paying more for a molecule buys anything — the question the premium page takes up from the pricing side.
The class against the alternatives
The first compared adults with obesity and documented asthma who started GLP-1-based therapy against adults who started a different weight-management drug, matched one to one, 2,423 per group, followed for a year. [1] Recorded asthma exacerbations were 1.7% against 4.0% — a risk difference of −2.2 percentage points, 95% CI −3.2 to −1.3, risk ratio 0.438, 95% CI 0.306 to 0.626.
Systemic steroid exposure was 16.4% against 23.1%. Emergency department or critical care use was 7.1% against 13.0%. Acute respiratory failure was 0.7% against 1.8%. Every secondary outcome pointed the same way.
One molecule against the other
The second study asked a narrower question: among people with asthma and type 2 diabetes, does it matter which one you start? [2] After matching, 8,176 patients in each group were followed twelve months. Asthma exacerbation occurred in 11.0% on tirzepatide and 11.1% on semaglutide — a hazard ratio of 1.00, 95% CI 0.91 to 1.10. The finding held across sensitivity and subgroup analyses.
On secondary outcomes, systemic corticosteroid use was the same, hazard ratio 1.01, 95% CI 0.96 to 1.05. Rescue inhaler use was marginally lower on tirzepatide, hazard ratio 0.92, 95% CI 0.88 to 0.96 — a difference small enough that in 16,352 matched patients almost anything separates, and not the kind of result anybody should pay a premium for.
Why the two results are not in tension
One compares a class against different drugs. The other compares two members of that class against each other. A large difference in the first and none in the second is the ordinary shape of a class effect: whatever is driving the respiratory benefit — most plausibly the weight loss — appears to be delivered by both molecules. That is not always how these drugs behave, and a class can split on another outcome entirely.
Worth noting that both studies draw on the same electronic health records network. They share its limitations rather than independently confirming one another, and neither randomized anybody.
The pricing consequence is direct. Across the 380 sellers here publishing both molecules by injection, read September 2026, tirzepatide runs a median of $60 more a month. On this outcome, in this population, that difference bought nothing measurable. It may buy a great deal on weight, where the head-to-head evidence is real — the current spread is worth reading against what each result actually covers.
What nobody is selling
No seller on this roster offers anything for asthma or claims a respiratory benefit, and neither study supports starting a GLP-1 for that purpose. What they support is narrower: if you have obesity and asthma and are already weighing one of these drugs, the respiratory picture is not a reason for concern, and it is not yet a reason in favor either.
Both papers call for randomized trials. Until those exist, this belongs in the same category as most secondary benefits in this market — plausible, consistently pointing one way, and measured in people who were not assigned to anything, which is the limit every matched-records study runs into.